document: the Qβ VLP-based therapeutics would not cause both liver and renal functions, and there were no signs of inflammation or antigenicity.23 Additionally, no significant body weight loss was observed in the mice treated with TrQβ VLPs or rQβ@b-3WJsiEGFR Let-7g or TrQβ@b-3WJsiEGFR Let-7g (Figure S22). The overall results indicate that TrQβ@b-3WJsiEGFR Let-7g-based genetic therapeutics are efficient and safe enough for use with low-dose X-ray irradiation in future clinical brain tumour treatment